New pill shows promise for rare lung cancer mutations

NCT ID NCT05168566

Recruiting now Disease control Sponsor: Teligene US Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called sutetinib in people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations (L861Q, G719X, or S768I). About 99 participants will take the drug by mouth to see if it shrinks tumors and how safe it is. The goal is to find a better treatment option for this specific group of patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sutetinib maleate capsule
What this could lead to: If successful, this could provide a new targeted treatment option for people with non-small cell lung cancer that has certain uncommon EGFR mutations.
What could go wrong: This is an early-phase (2b) study with only 99 participants, so results may not apply broadly. The drug may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Baptist Health
WITHDRAWN

Louisville, Kentucky, 40223, United States
Beijing Cancer Hospital
ACTIVE_NOT_RECRUITING

Beijing, Beijing Municipality, 100142, China
Beijing Chest Hospital
ACTIVE_NOT_RECRUITING

Beijing, Beijing Municipality, 101125, China
Cancer Hospital Chinese Academy of Medical Sciences
ACTIVE_NOT_RECRUITING

Beijing, Beijing Municipality, 100021, China
FirstHealth Cancer Center
RECRUITING

Pinehurst, North Carolina, 28374, United States
Harbin Medical University Cancer Hospital
ACTIVE_NOT_RECRUITING

Harbin, Heilongjiang, 150086, China
Henan Cancer Hospital
ACTIVE_NOT_RECRUITING

Zhengzhou, Henan, 450003, China
Hunan Cancer Hospital
ACTIVE_NOT_RECRUITING

Changsha, Hunan, 410006, China
Jiangsu Province Hospital
ACTIVE_NOT_RECRUITING

Nanjing, Jiangsu, 210029, China
Jilin Cancer Hospital
ACTIVE_NOT_RECRUITING

Changchun, Jilin, 130012, China
Linyi Cancer Hospital
ACTIVE_NOT_RECRUITING

Linyi, Shangdong, 276001, China
OPN Healthcare, Inc.
RECRUITING

Glendale, California, 91203, United States
Peking Union Medical College Hospital
ACTIVE_NOT_RECRUITING

Beijing, Beijing Municipality, 100730, China
Shanghai Chest Hospital
ACTIVE_NOT_RECRUITING

Shanghai, Shanghai Municipality, 200052, China
Shanghai Pulmonary Hospital
ACTIVE_NOT_RECRUITING

Shanghai, Shanghai Municipality, 200437, China
Sichuan Cancer Hospital
ACTIVE_NOT_RECRUITING

Chengdu, Sichuan, 610044, China
The Affiliated Cancer Hospital of Chongqin University
ACTIVE_NOT_RECRUITING

Chongqing, Chongqing Municipality, 400044, China
The First Affiliated Hospital of Bengbu Medical College
ACTIVE_NOT_RECRUITING

Bengbu, Anhui, 230000, China
The First Affiliated Hospital of China Medical University
ACTIVE_NOT_RECRUITING

Shengyang, Liaoning, 830000, China
The First Affiliated Hospital of Guangzhou Medical University
ACTIVE_NOT_RECRUITING

Guangzhou, Guangdong, 510230, China
The First Affiliated Hospital of Zhengzhou University
ACTIVE_NOT_RECRUITING

Zhengzhou, Henan, 450052, China
University Cancer & Blood Center
RECRUITING

Athens, Georgia, 30607, United States
University of Maryland Medical Center
RECRUITING

Baltimore, Maryland, 21201, United States
University of Texas MD Anderson Cancer Center
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States
Wuhan Union Hospital of China
ACTIVE_NOT_RECRUITING

Wuhan, Hubei, 430000, China
Zhejiang Cancer Hospital
ACTIVE_NOT_RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.